Core Viewpoint - 美中嘉和 (02453.HK) has entered into a placement agreement with Guotai Junan International to issue 48.72 million shares at a price of HKD 5.54 per share, representing approximately 18.38% of the existing H shares and 6.63% of the total issued shares as of the announcement date [1][2] Group 1: Placement Details - The placement involves 48.72 million shares, which will be issued under a general authorization [1] - The placement shares will account for approximately 15.52% of the enlarged issued H shares and about 6.22% of the total issued shares after the placement [1] Group 2: Use of Proceeds - The total expected proceeds from the placement are approximately HKD 270 million, with a net amount of about HKD 259 million [2] - The net proceeds will be allocated as follows: - Approximately HKD 77.63 million (30%) for the construction of Shanghai Taihe Cheng Tumor Hospital, expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 38.82 million (15%) to support the company's medical AI business, including operational and R&D expenses, also expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 64.69 million (25%) for repaying loans from financial institutions, including principal and interest for working capital loans and fixed asset loans, expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 77.63 million (30%) for replenishing the company's working capital and general corporate purposes, expected to be fully utilized by June 30, 2026 [2]

本报广州7月21日电（记者李刚）"香港长者医疗券大湾区试点计划"近日在广州番禺广东祈福医院正式 启用，符合资格的香港长者可使用医疗券支付该医院40个指定科室医疗服务费用。至此粤港澳大湾区内 地城市可以使用"医疗券"的服务点增至15个，超过178万名合资格的香港长者受惠。 启用首日，多名在内地居住的香港长者前往广东祈福医院咨询，数十人开通"医健通"账户并成功结算。 常住广州番禺祈福新邨的香港籍何女士，第一时间来体验香港长者医疗券大湾区试点计划"头啖汤"。她 在"长者医疗券专窗"出示香港身份证，工作人员熟练操作，认证过程快速完成，随即通过微信公众号轻 松完成挂号，从候诊、医生细致问诊，到开具药物处方，整个流程用时15分钟，费用直接用长者医疗券 抵扣。 香港长者医疗券大湾区试点计划是香港特区政府于2009年推出的一项便民政策，旨在为年满65岁的符合 资格香港长者提供每年2000港元的医疗券（累计上限为8000港元），让长者选用最符合自己健康需要的 医疗服务。2024年，香港特区政府开始推行"长者医疗券大湾区试点计划"，将医疗券的适用范围扩展至 大湾区9个内地城市。今年7月"长者医疗券大湾区试点计划"增加4个服务点， ...

Company Performance - Medpace reported quarterly earnings of $3.1 per share, exceeding the Zacks Consensus Estimate of $3 per share, and up from $2.75 per share a year ago, representing an earnings surprise of +3.33% [1] - The company posted revenues of $603.31 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 11.48%, compared to year-ago revenues of $528.1 million [2] - Over the last four quarters, Medpace has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Medpace shares have declined approximately 6.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $2.95 for the coming quarter and $12.68 for the current fiscal year [4][7] - The estimate revisions trend for Medpace was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Medpace belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The performance of Medpace's stock may also be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions [5][8]

Core Viewpoint - Tianyuan Medical (00557) announced a capital increase agreement involving its indirect subsidiaries, which aims to enhance the operational capacity of Shanghai Rifu and strengthen the group's competitiveness in the medical services sector in China [1][3]. Group 1: Capital Increase Agreement - Hengqin Hanyue Mei will increase its investment in Shanghai Rifu by RMB 15.5152 million (approximately HKD 16.9116 million) through the conversion of debt into equity [1]. - Shanghai Huaman will contribute an additional RMB 10 million (approximately HKD 10.9 million) in cash to Shanghai Rifu [1]. - Following the capital increase, Shanghai Rifu's registered capital will rise from RMB 2.3846 million to RMB 27.8998 million, while the shareholding ratios of Hengqin Hanyue Mei and Shanghai Huaman will remain unchanged at 60.8077% and 39.1923%, respectively [1]. Group 2: Shareholder Loan Agreement - On July 21, 2025, Shanghai Huaman will provide a shareholder loan of RMB 3 million (approximately HKD 3.27 million) to Shanghai Rifu, with a loan term of 36 months [1]. Group 3: Strategic Collaboration - The capital increase and shareholder loan are designed to meet the operational funding needs of Shanghai Rifu, thereby providing additional working capital for its daily operations [3]. - The collaboration with Shanghai Huaman, a marketing company in the medical beauty sector, is expected to enhance the group's strategic value and create potential cooperation opportunities with other medical beauty centers in China [3]. - This partnership is anticipated to bring further support and resources to Shanghai Rifu and the overall group, driving growth momentum [3].

Core Viewpoint - The China Securities Medical Advantage 50 Index has shown a recent upward trend, reflecting the performance of leading companies in the medical sector, despite a year-to-date decline. Group 1: Index Performance - The China Securities Medical Advantage 50 Index has increased by 5.31% over the past month and by 5.29% over the last three months, but has decreased by 2.32% year-to-date [2] - The index was established on December 31, 2015, with a base value of 1000.0 points [2] Group 2: Index Composition - The top ten weighted companies in the index are: Aier Eye Hospital (9.85%), Huatai Medical (9.05%), New Industry (6.52%), Aimeike (4.97%), United Imaging (4.72%), Mindray Medical (4.69%), Yuyue Medical (3.56%), Furuide (3.34%), Jianfan Bio (3.21%), and Lepu Medical (3.16%) [2] - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.14%) and the Shanghai Stock Exchange (39.86%) [2] Group 3: Industry Breakdown - The index's sample companies are categorized as follows: medical consumables (35.25%), medical devices (29.57%), in vitro diagnostics (25.33%), and medical services (9.85%) [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [3]

Group 1: Market Overview - The Hong Kong stock market is currently in a period of intensive mid-year earnings forecasts disclosure, with nearly 120 companies having released their forecasts as of July 18, resulting in a positive earnings forecast rate of 50.85% [1] Group 2: Companies with Significant Earnings Growth - Pop Mart expects its revenue to grow by no less than 200% and profit to increase by no less than 350% in the first half of the year, driven by enhanced brand recognition and diversified product offerings [3] - Huabao International anticipates a pre-tax profit of between 151.2 million to 177.2 million yuan, representing a growth of approximately 91.3% to 124.3% compared to the same period last year [3] - Guoquan expects a net profit of approximately 180 million to 210 million yuan, reflecting a growth of about 111% to 146% year-on-year, attributed to ongoing revenue growth and improved operational efficiency [4] - Zhou Hei Ya forecasts total revenue between 1.2 billion to 1.24 billion yuan, a slight decline of about 1.5% to 4.7% year-on-year, but expects profit to increase by 55.2% to 94.8% [4] - October Rice Field anticipates adjusted net profit of no less than 283 million yuan, a growth of at least 90% compared to the previous year, driven by innovation and deep operations in the home food category [5] - Andeli Juice expects a net profit of approximately 187 million to 214 million yuan, an increase of 40% to 60% year-on-year, due to increased customer orders and significant growth in concentrated juice sales [5] Group 3: Companies with Expected Earnings Decline - Conning Hospital projects a decline in net profit of approximately 25% to 35% compared to the same period last year, primarily due to reduced operating income from decreased average daily expenses per bed [7] - Xinyi Solar expects a net profit decline of 56% to 66% in the first half of 2025, attributed to a significant drop in average selling prices of solar glass products and an oversupply in the market [8] - Xinyi Glass anticipates a net profit decrease of 55% to 65%, driven by declining revenue and gross profit in the float glass business due to weak demand and market price pressures [8]

Core Viewpoint - The Hong Kong stock market is currently experiencing a concentrated period of mid-term earnings forecasts, with a notable number of companies expecting significant earnings growth [1]. Group 1: Positive Earnings Forecasts - Nearly 120 Hong Kong-listed companies have released earnings forecasts, with 37 companies expecting earnings growth, 14 companies turning losses into profits, and 9 companies anticipating slight increases. The overall positive earnings forecast rate stands at 50.85% [1]. - Pop Mart expects its revenue to grow by no less than 200% and profits to increase by no less than 350% compared to the same period last year, driven by enhanced brand recognition and diversified product offerings [3]. - Huabao International anticipates a pre-tax profit of between 151.2 million to 177.2 million yuan, representing a growth of approximately 91.3% to 124.3% year-on-year, primarily due to the absence of significant impairment losses this period [3]. - Guoquan expects a net profit of approximately 180 million to 210 million yuan, reflecting a growth of about 111% to 146% year-on-year, attributed to ongoing revenue growth and improved operational efficiency [4]. - Zhou Hei Ya forecasts total revenue between 1.2 billion to 1.24 billion yuan, a slight decline of 1.5% to 4.7% year-on-year, but expects profit growth of 55.2% to 94.8% due to optimized store structure and improved sales efficiency [4]. - October Rice Field anticipates adjusted net profit of no less than 283 million yuan, a growth of at least 90% year-on-year, driven by continuous innovation in home food categories and enhanced cooperation with quality sales channels [5]. - Andeli Juice expects a net profit of approximately 187 million to 214 million yuan, an increase of 40% to 60% year-on-year, mainly due to increased customer orders and significant growth in concentrated juice sales [5]. Group 2: Negative Earnings Forecasts - Some companies, such as Conning Hospital, expect a decline in mid-term earnings, with a projected drop in net profit of about 25% to 35% year-on-year, primarily due to reduced operating income from decreased average daily expenses per bed [7]. - Conning Hospital's previous report indicated a total revenue of 1.654 billion yuan for 2024, a year-on-year growth of 3.63%, but a net profit decline of 23.7% [8]. - Xinyi Solar anticipates a net profit decrease of 56% to 66% for the first half of 2025, attributed to a significant drop in average selling prices of solar glass products amid oversupply [8]. - Xinyi Glass expects a net profit decline of 55% to 65% for the same period, due to continuous revenue and gross profit declines in the float glass business, influenced by reduced demand and market price pressures [8].

转自：草原云 7月18日，通用技术航天医科内蒙古包钢医院（以下简称：内蒙古包钢医院）顺利通过中国医药教育协 会慢性气道疾病专委会全国"慢性气道疾病规范化管理建设项目"现场评估，正式成为全国第54家、内蒙 古自治区中西部首家项目单位。 2003年，内蒙古包钢医院挂牌成立全国第一家呼吸与危重症医学科，从那时起，呼吸与危重症学科的医 疗、教学、科研等工作全面开启。在科室主任杨敬平带领下，团队在科研创新、临床能力方面不断提升 壮大，年均接待患者近5万人次，逐渐发展成为包头及周边地区首屈一指的危重监护抢救中心。目前呼 吸与危重症医学科为国家临床重点专科。 现场评审过后，开始进行全国慢性气道疾病规范化管理建设项目管理人员培训，旨在进一步规范慢性气 道疾病的诊断和治疗，改善慢性气道疾病的管理现状和预后。 据悉，内蒙古包钢医院将以此次获评"全国慢性气道疾病规范化管理建设项目"为契机，促进慢性气道疾 病专科人才队伍的建设，更加规范、标准地开展慢性气道疾病的诊治，推动区域性慢性气道疾病防治提 质升级。 评审专家进行实地考察。 据悉，该项目由中国医药教育协会慢性气道疾病专业委员会发起，通过区域试点带头作用，推动基层医 疗机构慢性气 ...

Investment Rating - The industry investment rating is "Overweight" indicating a positive outlook for the sector in the next six months [1][29]. Core Insights - The pharmaceutical and biotechnology sector has shown strong performance, with an overall increase of 4.00% in the week from July 14 to July 18, outperforming the CSI 300 index by 2.91 percentage points [3][11]. - Year-to-date, the sector has risen by 16.59%, ranking third among 31 industries, and has outperformed the CSI 300 index by 13.45 percentage points [3][13]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 30.02 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index [3][17]. Market Performance - The pharmaceutical and biotechnology sector's sub-sectors that performed best last week include chemical pharmaceuticals (6.86%), biological products (3.68%), and medical services (3.14%) [3][11]. - A total of 397 stocks (82.88%) in the sector increased in value, while 70 stocks (14.61%) decreased [3][23]. - The top five performing stocks were: - Borui Pharmaceutical (42.35%) - Lisheng Pharmaceutical (41.68%) - Nanxin Pharmaceutical (34.95%) - Aosaikang (32.77%) - Yipinhong (32.13%) [3][24]. Industry News - The 11th batch of national centralized procurement was officially launched on July 15, with 55 drug varieties included, focusing on mature clinical drugs and excluding new drugs from procurement [4][25]. - He Yuan's plant-derived recombinant human serum albumin (HY1001) was approved for domestic marketing on July 18, aimed at treating liver cirrhosis with low albumin levels [4][26]. Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector remains a strong investment opportunity, particularly in innovative drugs, CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [5][27]. - Recommended stocks include: - Buy: Betta Pharmaceuticals, Teva Biologicals, Lao Baixing, Huaxia Eye Hospital, Qianhong Pharmaceutical, Baipusais [5][27]. - Focus: Kelun Pharmaceutical, Rongchang Biotechnology, Lizhu Group, Lingrui Pharmaceutical, Kaili Medical, Kangtai Biotechnology [5][27].

证券代码：002173 证券简称：创新医疗 公告编号：2025-045 创新医疗管理股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次担保情况概述 创新医疗管理股份有限公司（以下简称"公司"）子公司齐齐哈尔建华医院 有限公司（以下简称"建华医院"）因生产经营需要，拟向齐齐哈尔农村商业银 行股份有限公司（以下简称"齐齐哈尔农商行"）在人民币 2,520 万元的授信额 度内申请贷款延期，延期期限为一年。公司于 2025 年 7 月 21 日召开的第六届董 事会 2025 年第七次临时会议审议通过了《关于为建华医院提供担保的议案》，公 司知晓并同意为建华医院在 2,520 万元授信额度内向齐齐哈尔农商行申请贷款 延期提供连带责任担保。 根据《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管 指引第 1 号—主板上市公司规范运作》等法律法规和规范性文件及公司《章程》 的规定，上述担保事项无需提交公司股东大会审议。 二、被担保人基本情况 许可项目：医疗服务；食品销售。 一般项目：非居住房地产租赁：租赁服务（不含许可类租赁服务）；保健食 ...